Pharma News

The latest developments from pharmaceutical and biopharmaceutical companies, both innovator and generic-drug companies, and leading regulatory news.

Bayer has agreed to sell its global prescription dermatology unit to LEO Pharma, a Ballerup, Denmark-headquartered specialist in dermatology care. The portfolio to be acquired includes branded topical prescription treatments for acne, fungal skin...

The US Food and Drug Administration (FDA) has awarded a total of $6 million to three universities to study and recommend improvements for continuous manufacturing for drug substances and drug products. The awardees are Rutgers University, The...

Amgen has broken ground for a new biomanufacturing plant that will be constructed at its West Greenwich, Rhode Island campus. The new plant, worth up to $200 million, will manufacture products for the US and global markets. Amgen has labeled the...

Wockhardt, a Mumbai, India-headquartered pharmaceutical company, has inaugurated a new manufacturing facility in Dubai for producing new antibiotics. The facility is designed for producing and packaging sterile dry-powder drugs for injection. The...

Amgen has announced transition plans for two of its executive vice presidents (EVPs), Sean E. Harper, MD, EVP of Research and Development (R&D) and Anthony C. Hooper, currently EVP of Global Commercial Operations. After 16 years with Amgen,...

US Food and Drug Administration (FDA) Commissioner Scott Gottlieb has unveiled the agency’s Biosimilars Action Plan, which is part of the agency’s efforts to increase drug competition to address drug pricing. The FDA will hold a public meeting on...

Gilead Sciences has announced that John F. Milligan, PhD, President and Chief Executive Officer (CEO) and John C. Martin, PhD, Chairman, will step down from their roles. Milligan will remain in his current position through the end of the year...

GlaxoSmithKline (GSK) and 23andMe, a Mountain View, California-headquartered personal genomics and biotechnology company, have partnered for an exclusive four-year pact that will focus on research and development of new medicines using human...

Sangamo Therapeutics, a Richmond, California-based biopharmaceutical company, has agreed to acquire TxCell, a Valbonne, France-based biotechnology company developing personalized cellular immunotherapies, for approximately EUR 72 million ($84...